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P44 EXPRESSION OF CALCIUM/CALCINEURIN PATHWAY-REGU-
LATED TRANSCRIPTION FACTOR NFATC1 AND CHROMATIN-
REMODELLING GENES BRG1 AND BRM IN INVASIVE BREAST
CANCER
M. Pan. Division of Oncology, Kaiser Permanente Medical Centre, Santa
Clara, CA, USA
Background: NFATc1 is a transcription factor activated by the
calcium/calcineurin pathway, which regulates several physiolog-
ical processes. Evidence has also shown a role for NFAT transcrip-
tions factors in oncogenesis. BRG1 and BRM are chromatin-
remodelling genes that are also regulated by calcium homoeosta-
sis. Diminished expression of BRG1 is associated with poor prog-
nosis in breast cancer, non-small-cell lung cancer, colorectal
cancer, and prostate cancer. To understand the biological rela-
tionship between these two pathways, we examined the expres-
sion pattern of NFATc1, BRG1, and BRM in invasive breast cancer.
Methods: Paraffin blocks of 150 cases of invasive breast cancer
were retrieved from Kaiser Permanente Medical Centre database.
Monoclonal antibodies against NFATc1, BRG1, and BRM were
used, and expression pattern was determined as no expression,
weak (1+ staining intensity), moderate (2+), and high expression
(3+). Pearson Chi-Squared test was used for statistical analysis.
Findings: NFATc1 was expressed in approximately 22% of the
150 cases of invasive breast cancer, whereas BRG1 was expressed
in 56.7% and BRM in 52%. Both nuclear and cytoplasmic expres-
sion of NFATc1 was detected, with nuclear expression as the pre-
dominant feature. BRM1/BRM are predominantly expressed in the
nucleus. Most cases expressing NFATc1 showed 2+ moderate
intensity expression patterns. Statistical analysis showed that
expression of NFATc1 was highly correlated with the expression
of both BRG1 and BRM.
Interpretation: Our preliminary data shows that NFATc1 is
expressed in a subset of BRG1/BRM-positive invasive breast can-
cers. This correlation of two calcium homoeostasis-regulated
pathways provides insight into the oncogenesis of breast cancer.
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Background: Invasive fungal infections (IFI) vary considerably
worldwide and it is difficult to make a definitive microbiological
diagnosis. Therefore, we investigated the epidemiology of IFI by
use of panfungal PCR (PFPCR), during febrile episodes in patients
with haematological malignancies at Kidwai Memorial Institute
of Oncology – a Regional Cancer Centre for diagnosis, treatment,
and research on cancer in South India.
Methods: Over a period of 11 months, 160 febrile episodes in
125 patients with haematological malignancies undergoing treat-
ment at our institute were prospectively investigated for IFI. Fun-
gal DNA was extracted from whole blood, amplified by PFPCR
using primers against the conserved regions of fungal 18SrRNA
gene sequences, and speciated by dot-blot hybridisation.
Findings: 30 of the febrile episodes (19%) were positive for fun-
gal DNA, only two of which yielded fungal growth from blood. Fre-
quencies of proven, probable, possible IFI, and fungal DNAemia
without radiological or culture evidence were 1.3%, 0.63%, 5%,
and 12%, respectively. Infection by Candida species predominated
(22 of 30 [73%]), of which the majority were C.albicans [16 of 22
[73%]). Five of 22 (23%) were due to C.tropicalis. Infection due to
Aspergillus was rare (3%). Using EORTC criteria for defined IFI,
the sensitivity, specificity, positive, and negative predictive values
of PFPCR were 100%, 87%, 37%, and 100%, respectively.
Interpretation: Although fungal-DNA-positive febrile episodes
were seen in 19% of patients, the prevalence of IFI using the
revised EORTC criteria was 6.9%. Nevertheless, the high negative
predictive value of PFPCR makes it a reliable test that could allow
IFI to be excluded in patients with febrile neutropenia, and would
render unwarranted empirical antifungal treatment unnecessary.
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Background: We evaluated adverse events of nimotuzumab
combined with chemotherapy, radiotherapy, or chemoradiother-
apy in treatment of advanced carcinomas.
Methods: We reviewed 835 patients with pathologically diag-
nosed malignant tumours of stage II–IV with metastasis, who
were treated from January, 2010, until October, 2010, at 40 hospi-
tals nationwide, by nimotuzumab combined with radiotherapy,
chemotherapy, or chemoradiotherapy. Generally, patients were
receiving a dose of 45–72 Gy radiotherapy. Patients who were also
receiving chemotherapy were mainly receiving platinum agents.
All patients were receiving 100–200 mg nimotuzumab once a
week at the same time as the other therapies.
Findings: Medical records could be analysed in 792 cases, of
which 241 were nasopharyngeal cancer (28.86%); the next most
common type of malignancy was head and neck cancer (153 cases
[18.32%]). Patients were 37–75 years with a median age of 63.
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Male-to-female ratio was 5:2. In more than 90% of cases, the
pathology was squamous-cell carcinoma. Adenosquamous carci-
noma and adenocarcinomawere less than 10%. Cancers staged as
IV, III, and II made up 38.2%, 53.7%, and 10.1% of cases, respec-
tively, and 23.6% of cases involved metastasis. 22 patients
(2.63%) had adverse reactions that were unlikely to be due to nim-
otuzumab, including chills and fever in eight cases (0.96%), rash
in five cases (0.6%), oral mucositis in three cases (0.36%), gastroin-
testinal symptoms (vomiting or diarrhoea) in two cases (0.24%),
and dizziness in one case (0.12%). One patient had significant fati-
gue (0.12%), five had thrombocytopenia (0.6%), and five had
decreased white blood-cell count. Nimotuzumab-induced allergy
occurred in one case (0.12%).
Interpretation: Nimotuzumab combined with chemotherapy,
radiotherapy, or chemoradiotherapy for patients with advanced
carcinoma is well tolerated and safe.
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Background: We evaluated clinical outcomes and acute toxicity
in nasopharyngeal carcinoma treated with tomotherapy followed
by anti-EGFR monoclonal antibodies.
Methods: Between March, 2008, and November, 2009, 34
patients with newly diagnosed nasopharyngeal carcinoma were
treated with helical tomotherapy combined with nimotuzumab
(group N) or cetuximab (group C). All patients received tomother-
apy at 70 Gy/33F for the gross tumour volume (pGTVnx) and posi-
tive lymph nodes (GTVnd), 60Gy/33F for the high-risk clinical
target volume (CTV1), and 56 Gy/33F for the low-risk clinical tar-
get volume (CTV2). 17 patients in group N were given a weekly
injection of 200 mg/m2 for 6–7 weeks, and 17 patients in group
C were given an initial intravenous dose of 400 mg/m2 in the first
week, followed by weekly injections of 250 mg/m2 for 6–7 weeks.
Acute lesions were evaluated with the RTOG/EORTC criteria.
Findings The median follow-up was 22 months. Effective rates
(complete + partial responses) at 3, 6, and 12 months were 82.4%
(14/17), 70.6% (12/17), and 70.6% (12/17) in group N, and 88.2%
(15/17), 82.4% (14/17), and 82.4% (14/17) in group C. 1-year survival
was 88.2% (15/17) in group N and 100% (17/17) in group C. Nim-
otuzumab was associated with less acute mucositis (u = 2.245,
p < 0.05), weight loss (t 0 = 2.563, p = 0.0153) and rash (u = 4.362,
p < 0.01) than cetuximab.
Interpretation: Helical tomotherapy combined with nim-
otuzumab or cetuximab was effective for nasopharyngeal
carcinoma, and there was no difference in short-term efficacy
or 1-year survival. Nimotuzumab has fewer acute reactions than
cetuximab. More studies should be done to ascertain the long-
term effects.
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Background: We explored the efficacy of biological targeted
therapy combined with chemotherapy.
Methods: 71 patients (54 men and 17 women; age 30–83 years,
mean 60) were enrolled in this study. All patients had locally
advanced oral-maxillofacial and head and neck tumours (no indi-
cation for surgery or radiotherapy) confirmed by histology and
radiology, with indication for biochemotherapy. The chemother-
apy regimen given was cisplatin 75 mg/m2 day 1, paclitaxel
75 mg/m2 day 1, fluorouracil 750 mg/m2 days 1–5, and nim-
otuzumab 200 mg/m2 weekly.
Findings: Patients completed 2–4 cycles of chemotherapy
(mean 2.2). Nimotuzumab was given 2–8 times (mean 4.3). The
prognosis was as follows: complete response in four patients, par-
tial response in 39, stable disease in 18, and progressive disease in
3. Seven patients could not be evaluated. The total effective rate,
calculated as complete plus partial responses, was 61%. 29
patients had surgery after biochemotherapy. No serious adverse
reactions were noted during the course of the treatment, only
one case of slight erythra infection.
Interpretation: Nimotuzumab was effective in increasing
chemosensitivity and had a good tolerability profile.
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